Methylnaltrexone and Naloxone for Opioid-induced Constipation in the Critical Care Setting
| Autor: | Zara Alvi, Basant Elsharkawy, Muhammad Yasir, Bavandeep Singh, Harneel S Saini |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Constipation Stepdown unit oic Bowel perforation 030204 cardiovascular system & hematology Care setting 03 medical and health sciences 0302 clinical medicine Naloxone medicine Intensive care medicine business.industry Gastroenterology General Engineering constipation Methylnaltrexone Opioid induced constipation Neurology Opioid opioid Preventive Medicine medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.6829 |
| Popis: | Opioid antagonists in the ICU are often a last-line medication given to patients with opioid-induced constipation. Traditionally, patients have been administered nonopioid-based bowel regimens such as senna, peg, and docusate to treat constipation. Despite the obvious need to treat acute pain with opioids, side effects such as constipation can lead to multiple gastrointestinal (GI) complications such as bowel perforation and even death. Specifically, opioid-induced constipation (OIC) can be very difficult to treat. We examine naloxone and methylnaltrexone (MNTX) assessing GI complications and OIC as well as present a patient case which highlights the importance of treating OIC. We also evaluate the superior reversal agent of choice when treating OIC in the critical care and stepdown unit settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|